JACC:一种新型的自膨式可复位心脏瓣膜

2018-12-12 MedSci MedSci原创

新型自膨式可复位的经导管心脏瓣膜(THV)系统是被设计用于治疗严重的有临床症状且外科风险的主动脉瓣狭窄患者。本研究的目的旨在评估该新型THV系统的1年疗效。本次多中心临床试验是用于评估植入该新型THV后30天、1年和5年的预后,主要终点事件是术后1年的全因死亡率,次要终点事件是临床预后和心超指标。最终共纳入941名患者(82.4 ± 5.9岁,女性占65.7%),术后1年,全因死亡率、心血管死亡率

新型自膨式可复位的经导管心脏瓣膜(THV)系统是被设计用于治疗严重的有临床症状且外科风险的主动脉瓣狭窄患者。本研究的目的旨在评估该新型THV系统的1年疗效。

本次多中心临床试验是用于评估植入该新型THV后30天、1年和5年的预后,主要终点事件是术后1年的全因死亡率,次要终点事件是临床预后和心超指标。最终共纳入941名患者(82.4 ± 5.9岁,女性占65.7%),术后1年,全因死亡率、血管死亡率、致残性卒中率和心梗发生率分别是 12.1%, 6.6%, 2.2%和2.5%,平均主动脉瓣跨瓣压差和主动脉瓣面积分别是 8.66 mm Hg和1.75 cm2,术后30天和1年的新发起搏器率为18.7%和21.3%。另外,患者术后1年的功能分级、运动量和生活质量均有所改善。

研究结果显示,该新型自膨式可复位的经导管心脏瓣膜在治疗外科风险的严重主动脉瓣狭窄患者术后1年的死亡风险和卒中风险均较低,血流动力学的指标也较好。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1715952, encodeId=a32c1e15952b4, content=<a href='/topic/show?id=2c375156e5f' target=_blank style='color:#2F92EE;'>#心脏瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51567, encryptionId=2c375156e5f, topicName=心脏瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b6d32099965, createdName=jianjun77, createdTime=Mon Apr 22 01:40:00 CST 2019, time=2019-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854250, encodeId=2dc218542509b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue May 14 17:40:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326063, encodeId=21831326063bf, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Dec 14 00:40:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583597, encodeId=137c158359eae, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Fri Dec 14 00:40:00 CST 2018, time=2018-12-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1715952, encodeId=a32c1e15952b4, content=<a href='/topic/show?id=2c375156e5f' target=_blank style='color:#2F92EE;'>#心脏瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51567, encryptionId=2c375156e5f, topicName=心脏瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b6d32099965, createdName=jianjun77, createdTime=Mon Apr 22 01:40:00 CST 2019, time=2019-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854250, encodeId=2dc218542509b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue May 14 17:40:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326063, encodeId=21831326063bf, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Dec 14 00:40:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583597, encodeId=137c158359eae, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Fri Dec 14 00:40:00 CST 2018, time=2018-12-14, status=1, ipAttribution=)]
    2019-05-14 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1715952, encodeId=a32c1e15952b4, content=<a href='/topic/show?id=2c375156e5f' target=_blank style='color:#2F92EE;'>#心脏瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51567, encryptionId=2c375156e5f, topicName=心脏瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b6d32099965, createdName=jianjun77, createdTime=Mon Apr 22 01:40:00 CST 2019, time=2019-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854250, encodeId=2dc218542509b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue May 14 17:40:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326063, encodeId=21831326063bf, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Dec 14 00:40:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583597, encodeId=137c158359eae, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Fri Dec 14 00:40:00 CST 2018, time=2018-12-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1715952, encodeId=a32c1e15952b4, content=<a href='/topic/show?id=2c375156e5f' target=_blank style='color:#2F92EE;'>#心脏瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51567, encryptionId=2c375156e5f, topicName=心脏瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b6d32099965, createdName=jianjun77, createdTime=Mon Apr 22 01:40:00 CST 2019, time=2019-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854250, encodeId=2dc218542509b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue May 14 17:40:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326063, encodeId=21831326063bf, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Dec 14 00:40:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583597, encodeId=137c158359eae, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Fri Dec 14 00:40:00 CST 2018, time=2018-12-14, status=1, ipAttribution=)]

相关资讯

Lancet Diabetes Endocrinol:糖尿病药物利拉鲁肽或能有效降低患者心血管疾病事件的风险

利拉鲁肽的使用还与患者心血管疾病死亡风险降低以及任何原因导致的死亡风险降低直接相关,在亚群分析中,研究者指出,有心血管疾病史的患者似乎会因利拉鲁肽疗法而获益,尽管其与无疾病史患者之间并无统计学意义。最后研究者Bjorn Pasternak说道,本文研究表明,药物利拉鲁肽在更广泛的未选择的患者群体中能带来心血管健康的益处,同时还能提供重要的临床验证证据。

盘点:JACC十二月第一期研究一览

1.自膨式经导管主动脉瓣置换术与外科主动脉瓣置换术5年预后比较DOI: 10.1016/j.jacc.2018.08.2146http://www.onlinejacc.org/content/72/22/2687本研究的目的旨在比较和评估美国关键高风险CoreValve 临床试验中经导管主动脉瓣置换术(TAVR)和外科主动脉瓣置换术(SAVR)的5年预后。本次临床试验将外科高风险患者随机1:1分

JACC:SYNTAX 评分在糖尿病伴复杂冠心病患者中的应用

糖尿病(DM)与复杂型冠心病的发生相关,从而增加了心血管并发症的发病率和死亡率。本研究的目的旨在通过SYNTAX 评分(SS)预测接受冠脉搭桥(CABG)或经皮冠脉介入治疗(PCI)的糖尿病伴复杂冠心病患者的心血管预后。本研究纳入分析了FREEDOM 临床试验中的患者,硬性心血管终点事件(HCE)为全因死亡、非致死性心梗和非致死性卒中的复合事件,主要不良心脑血管事件(MACCE)为HCE和反复性血

JAMA Netw Open:地中海饮食与妇女心血管疾病的风险关系

已有的研究显示,摄入地中海饮食(MED)与心血管疾病(CVD)的风险降低有关,但至今为止,关于人群中这种反向疾病关联的潜在分子机制的数据有限。

JACC:冠脉搭桥和经皮介入治疗的10年预后比较

既往已有研究报道了冠脉搭桥(CABG)和经皮导管介入术(PCI)在治疗左冠状动脉主干病变(LMCA)预后疗效中的差异,但其超远期的预后比较尚不清楚。本研究的目的旨在评估和比较CABG和PCI在治疗LMCA十年后的疗效。本研究纳入分析了MAIN-COMPARE临床研究中的2240名LMCA患者 ,其中1102名接受了PCI治疗,1138名接受了CABG治疗,经过10年随访分析后,发现两组患者在死亡风

J Diabetes Investig:代谢综合征增加糖尿病前期患者心血管风险

一项最新研究结果显示,在中国成人糖尿病前期患者中,代谢综合征使主要心血管事件发生风险增加。